![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Bossi Paolo Locati Laura Licitra Lisa
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.18, Iss.4, 2013-12, pp. : 445-459
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Emerging tyrosine kinase inhibitors for esophageal cancer
By Ku Geoffrey Y Ilson David H
Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Emerging drugs for head and neck cancer
By Rhee John C Khuri Fadlo R Shin Dong M
Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Protein tyrosine kinase inhibitors in cancer treatment
By Traxler P.M.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tyrosine kinase inhibitors in cancer treatment (Part II)
By Traxler P.
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 12, 1998-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. :